Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP3 | P08254 | 2/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7907806 | 0.90 | ADAM17 (0.58) | MMP2MMP9ADAM17CACNA1FALDH1A1 | |
| Hydrochloric Acid SCHEMBL23354268 | 0.88 | ADAM17 (0.56) | MMP2MMP9ADAM17CACNA1FALDH1A1 | |
| SCHEMBL5955905 | 0.80 | ADAM17 (0.50) | MMP2ADAM17MMP8MMP14MMP17 | |
| SCHEMBL10112557 | 0.80 | ADAM17 (0.41) | MMP2MMP9ADAM17CYP3A4MMP8 | |
| SCHEMBL7900340 | 0.80 | ADAM17 (0.41) | MMP2MMP9ADAM17CYP3A4MMP8 | |
| SCHEMBL29873928 | 0.77 | MMP13 (0.52) | ADAM17ALDH1A1CYP3A4MMP8MMP14 | |
| SCHEMBL23367191 | 0.77 | MMP13 (0.52) | ADAM17ALDH1A1CYP3A4MMP8MMP14 | |
| Hydrochloric Acid SCHEMBL23354880 | 0.75 | MMP13 (0.51) | ADAM17ALDH1A1CYP3A4MMP8MMP14 | |
| Hydrochloric Acid SCHEMBL29873539 | 0.75 | MMP13 (0.51) | ADAM17ALDH1A1CYP3A4MMP8MMP14 | |
| SCHEMBL4123231 | 0.73 | ADAM17 (0.62) | MMP2MMP9ADAM17CACNA1FALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976849-B1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME (US) | 2016-03-09 | — | — | EP | disclosed |
| US-7879890-B2 | hydantoin derivatives that can inhibit matrix metalloproteinases and tumor necrosis factor alpha-converting enzyme, to prevent the release of tumor necrosis factor; treatment of septic shock, reperfusion injuries, meningitis, psoriasis, arthritis, inflammatory bowel disease and ankylosing spondylitis | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7687527-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7683085-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090111803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-04-30 | — | — | US | disclosed |
| US-7504424-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7482370-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| WO-2007084415-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | MMP2 33/4885MMP9 17/4885MMP3 8/4885 |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | MMP2 30/4885MMP9 23/4885MMP3 11/4885 |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | MMP2 30/4885MMP9 23/4885MMP3 11/4885 |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | MMP2 30/4885MMP9 23/4885MMP3 11/4885 |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | MMP2 30/4885MMP9 23/4885MMP3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.